Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 10/20 | 1.00 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12563256 | 0.89 | PNMT (0.79) | PNMTMEN1TSHRCYP2C19RAB9A | |
| SCHEMBL13560077 | 0.86 | PNMT (0.75) | PNMTMEN1TSHRCYP2C19RAB9A | |
| Trifluoroacetic Acid SCHEMBL17965628 | 0.84 | PNMT (0.71) | PNMTTPSAB1TPSD1TPSG1 | |
| SCHEMBL4709086 | 0.84 | PNMT (0.72) | PNMTCD44MAOBADRA2AADRA2B | |
| SCHEMBL23491280 | 0.81 | — | — | |
| SCHEMBL21236155 | 0.78 | PNMT (0.63) | PNMTCD44MAOBTPSAB1TPSD1 | |
| SCHEMBL12563262 | 0.77 | PNMT (0.62) | PNMTMEN1TSHRCYP2C19RAB9A | |
| SCHEMBL1427612 | 0.76 | PNMT (0.61) | PNMTCD44MAOBTPSAB1TPSD1 | |
| SCHEMBL17613134 | 0.76 | PNMT (0.61) | PNMTCD44MAOBTPSAB1TPSD1 | |
| SCHEMBL12126395 | 0.76 | PNMT (0.61) | PNMTCD44MAOBTPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024071398-A1 | ABHD6 ANTAGONIST | 小野薬品工業株式会社 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023116812-A1 | SULFONYLUREA COMPOUND | 瑞石生物医药有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-113387959-B | Synthesis method of thieno [3,2-c ] pyridine-6-carboxylic acid methyl ester | 烟台理工学院 | 2023-05-05 | — | — | CN | disclosed |
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| EP-3887372-B1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021113686-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-3484879-B1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2020-12-30 | — | — | EP | disclosed |
| WO-2019192506-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2019-10-10 | — | — | WO | disclosed |
| EP-3524602-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
| US-20100063023-A1 | Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors | WYETH (US) | 2010-03-11 | — | — | US | disclosed |
| US-20070185077-A1 | Methods of treating, preventing and inhibiting cancer metastasis and tumor formation | WASHINGTON UNIVERSITY | 2007-08-09 | — | — | US | disclosed |
| US-20070185077-A1 | Methods of treating, preventing and inhibiting cancer metastasis and tumor formation | WASHINGTON UNIVERSITY | 2007-08-09 | — | — | US | disclosed |
| WO-2005044978-A9 | METHODS OF TREATING, PREVENTING AND INHIBITING CANCER METASTASIS AND TUMOR FORMATION | UNIV WASHINGTON (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005044978-A2 | METHODS OF TREATING, PREVENTING AND INHIBITING CANCER METASTASIS AND TUMOR FORMATION | WASHINGTON UNIVERSITY (US) | 2005-05-19 | — | — | WO | disclosed |
| EP-1057814-B1 | TETRAHYDROBENZINDOLE DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-6498251-B1 | Tetrahydrobenzindole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| US-6407112-B1 | 2A,3,4,5-TETRAHYDRO-1H-BENZ(CD)INDOL-2-ONE DERIVATIVES; 5-HYDROXYTRYPTAMINE AGONISTS; SLEEP, CIRCADIAN RHYTHYM, BIPOLAR, AND PSYCHOLOGICAL DISORDER TREATMENT | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1081136-A1 | OPTICALLY ACTIVE TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
| EP-1057814-A1 | TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | ABL1, BTK, LYN | PNMT 2859/4885CD44 4569/4885MAOB 1005/4885 |
| US-20070185077-A1 | Methods of treating, preventing and inhibiting cancer metastasis and tumor formation | ITGB3, ITGB1, ITGA2B | PNMT 3600/4885CD44 227/4885MAOB 2302/4885 |
| US-20100063023-A1 | Bicyclic and Tricyclic Substituted 6-Methylidene Carbapenems as Broad Spectrum Beta-Lactamase Inhibitors | MGAM, CYP2C18, BCAT2 | PNMT 1278/4885CD44 3883/4885MAOB 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.